A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension

Completed · Phase 4

Conditions studied: Glaucoma, Ocular Hypertension

In brief

This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P) in combination in patients previously treated with latanoprost 0.005% ophthalmic solution monotherapy who require additional intraocular pressure (IOP) lowering medication.

Key facts

Study ID

NCT01525173

Run by

Allergan

People needed

137

Starts

2012-01-01

Expected to finish

2012-10-01

Last updated by the study team

2013-12-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ocular hypertension or glaucoma in at least 1 eye
• Visual acuity of 20/100 or better in both eyes

You may not qualify if…

• Corneal refractive laser surgery (LASIK, LASEK, PRK, RK) in the study eye(s)
• Intraocular or glaucoma surgery in the past 3 months

Where it is running

• Study site — Deerfield Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.